GLP-1 goliath updates demand for top weight loss drug

thestreet.com/investing/stocks/glp-1-goliath-updates-demand-for-top-weight-loss-drug

Novo Nordisk reported Q3 2025 earnings on November 5, showing continued strong demand for its weight-loss drug Wegovy, despite rising costs and pricing pressure forcing the company to narrow its full-year guidance.
Novo Nordisk financial results
The drugmaker reported a 15% increase in…

This story appeared on thestreet.com, 2025-11-05 18:24:41.
The Entire Business World on a Single Page. Free to Use →